(Q34743086)

4 August 2017

1 reference

title

Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs (English)

1 reference

4 August 2017

Nicos A Petasis

5

0 references

author name string

Axel H Schönthal

1

1 reference

4 August 2017

Thomas C Chen

2

1 reference

4 August 2017

Florence M Hofman

3

1 reference

4 August 2017

Stan G Louie

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Expert Opinion on Investigational Drugs

4 August 2017

1 reference

4 August 2017

17

1 reference

4 August 2017

2

1 reference

4 August 2017

197-208

1 reference

Cyclooxygenases: structural, cellular, and molecular biology

4 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

COX-2 inhibitors and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Targeting cyclooxygenase-2 in human neoplasia: rationale and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cancer prevention: a new era beyond cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Aspirin, NSAIDS, and colon cancer prevention: mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib inhibits interleukin-12 alphabeta and beta2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib transiently inhibits cellular protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

A novel celecoxib derivative potently induces apoptosis of human synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non-COX-2 inhibitory analog of celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Tumorigenesis and the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cerebrospinal fluid and plasma pharmacokinetics of the cyclooxygenase 2 inhibitor rofecoxib in humans: single and multiple oral drug administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Metabolism of rofecoxib in vitro using human liver subcellular fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Efficacy of celecoxib in the treatment of CNS lymphomas: an in vivo model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cyclooxygenase 2 inhibitors: discovery, selectivity and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib for the prevention of sporadic colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib for the prevention of colorectal adenomatous polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.2.197

10.1517/13543784.17.2.197

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference